Laura M. DeBusk

2.8k total citations · 1 hit paper
26 papers, 2.3k citations indexed

About

Laura M. DeBusk is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Laura M. DeBusk has authored 26 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Laura M. DeBusk's work include Angiogenesis and VEGF in Cancer (10 papers), HER2/EGFR in Cancer Research (5 papers) and Cell Adhesion Molecules Research (5 papers). Laura M. DeBusk is often cited by papers focused on Angiogenesis and VEGF in Cancer (10 papers), HER2/EGFR in Cancer Research (5 papers) and Cell Adhesion Molecules Research (5 papers). Laura M. DeBusk collaborates with scholars based in United States, Italy and Canada. Laura M. DeBusk's co-authors include P. Charles Lin, Yang Li, Lynn M. Matrisian, Yu Shyr, Barbara Fingleton, David P. Carbone, John C. Gore, Thomas E. Yankeelov, Claudio Russo and Jan K. Teller and has published in prestigious journals such as Nature Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Laura M. DeBusk

26 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

2004 936 citations Yang Li, Laura M. DeBusk et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura M. DeBusk United States	18	892	761	721	348	346	26	2.3k
Florence Boissière‐Michot France	25	775 0.9×	597 0.8×	1.3k 1.8×	308 0.9×	182 0.5×	75	2.3k
Vanitha Ramakrishnan United States	17	784 0.9×	289 0.4×	500 0.7×	244 0.7×	102 0.3×	32	2.8k
Christian Wallasch Germany	11	2.3k 2.6×	369 0.5×	1.1k 1.5×	466 1.3×	231 0.7×	14	3.5k
Lisa Happerfield United Kingdom	27	995 1.1×	339 0.4×	656 0.9×	152 0.4×	318 0.9×	43	2.4k
Lauri Miller United States	12	998 1.1×	273 0.4×	444 0.6×	211 0.6×	107 0.3×	16	2.1k
Tadahisa Shono Japan	21	956 1.1×	317 0.4×	391 0.5×	130 0.4×	95 0.3×	64	2.2k
Kazuhito Ichikawa Japan	27	1.7k 1.9×	347 0.5×	643 0.9×	152 0.4×	371 1.1×	96	3.2k
Wentian Yang United States	30	2.2k 2.5×	1.4k 1.9×	750 1.0×	95 0.3×	461 1.3×	51	3.5k
Norbert Prenzel Germany	9	2.2k 2.4×	327 0.4×	1.3k 1.8×	421 1.2×	178 0.5×	9	3.6k
Na Niu China	25	834 0.9×	337 0.4×	438 0.6×	144 0.4×	227 0.7×	103	2.1k

Countries citing papers authored by Laura M. DeBusk

Since Specialization

Citations

This map shows the geographic impact of Laura M. DeBusk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura M. DeBusk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura M. DeBusk more than expected).

Fields of papers citing papers by Laura M. DeBusk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura M. DeBusk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura M. DeBusk. The network helps show where Laura M. DeBusk may publish in the future.

Co-authorship network of co-authors of Laura M. DeBusk

This figure shows the co-authorship network connecting the top 25 collaborators of Laura M. DeBusk. A scholar is included among the top collaborators of Laura M. DeBusk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura M. DeBusk. Laura M. DeBusk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Yardley, Denise A., N. W. Peacock, Brooke Daniel, et al.. (2020). Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 180(3). 647–655. 5 indexed citations

2.

Yardley, Denise A., William H. Liggett, Mark Mainwaring, et al.. (2019). A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer. 20(2). 89–97. 6 indexed citations

3.

Yardley, Denise A., Lowell L. Hart, Patrick J. Ward, et al.. (2018). Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study. Clinical Breast Cancer. 18(5). e781–e787. 12 indexed citations

4.

Yardley, Denise A., Dianna Shipley, Patrick J. Ward, et al.. (2018). A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. Clinical Breast Cancer. 19(1). 1–9. 7 indexed citations

5.

Ko, Andrew H., Patrick Murphy, James D. Peyton, et al.. (2017). A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. The Oncologist. 22(12). 1427–e129. 38 indexed citations

6.

Savona, Michael R., Zeqiang Ma, Laura M. DeBusk, et al.. (2013). Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis. Blood. 122(21). 5266–5266. 2 indexed citations

7.

Yu, Yang, Tracy Criswell, Laura M. DeBusk, et al.. (2010). Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene. 29(23). 3335–3348. 38 indexed citations

8.

DeBusk, Laura M., Kimberly Boelte, Yongfen Min, & P. Charles Lin. (2010). Heterozygous deficiency of δ-catenin impairs pathological angiogenesis. The Journal of Experimental Medicine. 207(1). 77–84. 24 indexed citations

9.

DeBusk, Laura M., Kimberly Boelte, Yongfen Min, & P. Charles Lin. (2010). Heterozygous deficiency of δ-catenin impairs pathological angiogenesis. The Journal of Experimental Medicine. 207(3). 669–669. 23 indexed citations

10.

Lin, Ping‐Chang, et al.. (2007). Expansion of Myeloid Immune Suppressor Cells in Tumor-bearing Host Directly Promotes Tumor Angiogenesis, Tumor Growth, and Metastasis. Clinical Cancer Research. 13. 3 indexed citations

11.

Kamiyama, Masako, Ambra Pozzi, Lin Yang, et al.. (2006). EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene. 25(53). 7019–7028. 108 indexed citations

12.

Yankeelov, Thomas E., Laura M. DeBusk, Dean Billheimer, et al.. (2006). Repeatability of a reference region model for analysis of murine DCE‐MRI data at 7T. Journal of Magnetic Resonance Imaging. 24(5). 1140–1147. 56 indexed citations

13.

Yankeelov, Thomas E., Jeffrey J. Luci, Martin Lepage, et al.. (2005). Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magnetic Resonance Imaging. 23(4). 519–529. 227 indexed citations

14.

Chen, Ying, Edwin F. Donnelly, Hanako Kobayashi, Laura M. DeBusk, & P. Charles Lin. (2005). Gene therapy targeting the Tie2 function ameliorates collagen‐induced arthritis and protects against bone destruction. Arthritis & Rheumatism. 52(5). 1585–1594. 48 indexed citations

15.

Li, Yang, Laura M. DeBusk, Barbara Fingleton, et al.. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 6(4). 409–421. 936 indexed citations breakdown →

16.

DeBusk, Laura M., Dennis E. Hallahan, & P. Charles Lin. (2004). Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Experimental Cell Research. 298(1). 167–177. 103 indexed citations

17.

Chen, Jian‐Xiong, et al.. (2004). Dual functional roles of Tie-2/angiopoietin in TNF-α-mediated angiogenesis. American Journal of Physiology-Heart and Circulatory Physiology. 287(1). H187–H195. 67 indexed citations

18.

DeBusk, Laura M., et al.. (2003). Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α–induced angiogenesis in rheumatoid arthritis. Arthritis & Rheumatism. 48(9). 2461–2471. 82 indexed citations

19.

Russo, Claudio, Takaomi C. Saido, Laura M. DeBusk, et al.. (1997). Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains. FEBS Letters. 409(3). 411–416. 111 indexed citations

20.

Teller, Jan K., Claudio Russo, Laura M. DeBusk, et al.. (1996). Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome. Nature Medicine. 2(1). 93–95. 280 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact